No Data
No Data
Earnings Preview: Genmab to Report Financial Results on May 08
Sector Update: Health Care Stocks Rise Premarket Friday
William Blair Maintains Genmab(GMAB.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Genmab (GMAB) and Envista Holdings (NVST)
Genmab to Seek US FDA Approval for Follicular Lymphoma Therapy Combination Drug
Genmab to Submit Supplemental Biologics License Application (SBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients With Relapsed/Refractory Follicular Lymphoma (FL)